Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Informed Consent Formats by Information Preference and Priority

24 de janeiro de 2018 atualizado por: Carnegie Mellon University
This study will test whether different formats of medical informed consent documents can help improve understanding and confidence in decision-making for clinical trials. The study will be primarily run through an online survey.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

The goal of this study is to investigate whether the same information can be communicated in different formats of an informed consent document in ways that improve participant understanding and confidence. Participants will review one of several different versions of the same informed consent document, and will be asked to complete a survey after reading the documents. The survey will ask participants their willingness to enroll in the clinical trial discussed in the document and their confidence in their decision. The survey will also test participants recollection of information from the informed consent document. Researchers will look at this data to see if there are ways to improve knowledge about the clinical trial and confidence in decisions without necessarily changing enrollment preferences.

Tipo de estudo

Intervencional

Inscrição (Real)

500

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Estados Unidos
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15213
        • Carnegie Mellon University

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • 18 Years Old or Older
  • Read and agreed to informed consent
  • Indicated desire to participate
  • Diagnosed with asthma
  • US resident

Exclusion Criteria:

  • Participants from whom we receive multiple responses will be dropped from analysis (but will be compensated for participation)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Original
Participants will review the full-length, original consent form for the clinical trial.
Comportamental: Original consent form
Participants will review the full-length, original consent form for the clinical trial.
Experimental: Shortened
Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
Comportamental: Shortened consent form
Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
Experimental: Reordered
Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
Comportamental: Reordered, shortened consent form
Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
Experimental: Highlighted
Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
Comportamental: Shortened consent form with a highlights box
Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
Experimental: Interactive
Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
Comportamental: Interactive, shortened consent form
Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Score for high impact questions
Prazo: through study completion, an average of 30 minutes
Sum of correct answers (T/F) for any item relating to material that was rated as 50 or higher on impact on willingness to enroll in a previous study.
through study completion, an average of 30 minutes

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Score for low impact questions
Prazo: through study completion, an average of 30 minutes
Sum of correct answers (T/F) for any item relating to material that was rated as 49 or lower on impact on willingness to enroll in a previous study.
through study completion, an average of 30 minutes
Total score for all questions
Prazo: through study completion, an average of 30 minutes
Sum of correct answers (T/F) on full knowledge test.
through study completion, an average of 30 minutes
Interaction effect of format and importance on likelihood of correct answer
Prazo: through study completion, an average of 30 minutes
Interaction effect in a logistic regression predicting a correct answer, based on the format of the consent form and the importance of the answer.
through study completion, an average of 30 minutes
Scores for different information categories
Prazo: through study completion, an average of 30 minutes
Sum of correct answers (T/F) for each of the 20 information categories
through study completion, an average of 30 minutes
Effect of location on score
Prazo: through study completion, an average of 30 minutes
Logistic regression coefficient of likelihood of predicting a correct answer, based upon the location on which the sentence appeared--uses only the shortened, and the reordered conditions. Note that sentences appearing in the introduction (which is the first section of all treatments) must be dropped, as there will be no variation in location.
through study completion, an average of 30 minutes
Decision to enroll
Prazo: through study completion, an average of 30 minutes
Likert measure of participants hypothetical decision to enroll in the study
through study completion, an average of 30 minutes
Confidence in enrollment decision
Prazo: through study completion, an average of 30 minutes
Likert measure of participants confidence in hypothetical decision to enroll in the study
through study completion, an average of 30 minutes
Satisfaction with consent structure
Prazo: through study completion, an average of 30 minutes
Likert measure of participants satisfaction with the consent form
through study completion, an average of 30 minutes
Perception of investigator concern for well being
Prazo: through study completion, an average of 30 minutes
Likert measure of participants belief in the investigator's concerns for the participant's well-being
through study completion, an average of 30 minutes
Perception of investigator transparency
Prazo: through study completion, an average of 30 minutes
Likert measure of participants belief that the investigator is trying to communicate information about the trial accurately
through study completion, an average of 30 minutes
Participant's probability estimate of the likelihood that the treatment would help control their asthma
Prazo: through study completion, an average of 30 minutes

Survey question of the following form:

'If you enrolled in the trial described in the consent form, what is the probability that the treatment could help control your asthma better, where 0% means "no chance at all of helping" and 100% means "would definitely help"?'

Participants provided with drop-down menu including values from 0% to 100% in increments of 1%.
through study completion, an average of 30 minutes

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Participant's free-response text describing what was learned from reading the informed consent document
Prazo: through study completion, an average of 30 minutes

Survey question of the following form:

"What are some of the key things you learned from reading the informed consent document?"

Participants are then provided with an free-response text box where they are allowed to enter whatever text they want, as long as they enter some text. These responses will be coded by two independent coders, blinded to the treatment arms, using an emergent coding system to identify different topics that participants may raise.
through study completion, an average of 30 minutes

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Carnegie Mellon University

Colaboradores

ICON plc

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

27 de novembro de 2017

Conclusão Primária (Real)

31 de dezembro de 2017

Conclusão do estudo (Real)

31 de dezembro de 2017

Datas de inscrição no estudo

Enviado pela primeira vez

8 de janeiro de 2018

Enviado pela primeira vez que atendeu aos critérios de CQ

24 de janeiro de 2018

Primeira postagem (Real)

31 de janeiro de 2018

Atualizações de registro de estudo

Última Atualização Postada (Real)

31 de janeiro de 2018

Última atualização enviada que atendeu aos critérios de controle de qualidade

24 de janeiro de 2018

Última verificação

1 de janeiro de 2018

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Outros números de identificação do estudo

  • STUDY2017_00000268

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

Intend to share deidentified participant data, but we want to review the received data to ensure that there is no information that could potentially reveal individual identity that we may not initially anticipate. As such, a clear delineation of what data will be disclosed is not yet available.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Original consent form

Pesquisar ensaios semelhantes

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

CROs by country

CROs in Germany

Condições

Doenças Raras

Intervenções de drogas

Suplementos Alimentares

Patrocinador / Colaboradores

Localizações

Se inscrever